Genetic alterations, including mutation, gene amplification, or chromosomal rearrangement in the anaplastic lymphoma kinase (ALK) gene, are detected in 3 to 8% of patients with non-small cell lung cancer (NSCLC) [1, 2]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.